Horizon Megadeal: J&J Out, Experts Say Sanofi Could Have Edge On Amgen

06 Dec 2022

• By Ayisha Sharma

Janssen has dropped out of the running to acquire Irish biotech Horizon, leaving Sanofi and Amgen to vie over the potential megadeal, with some observers identifying the former as the better fit.

Two people running in race against sunset horizon background — Sanofi And Amgen Remain In The Race For Horizon • Source: Shutterstock

Janssen Pharmaceuticals Inc. has revealed it has no intention to place a bid on Horizon Therapeutics plc less than a week after the Dublin-based biotech was forced to reveal under Irish Takeover Rules that it was engaging in early discussions with three big pharma firms.

J&J dropping out of the race leaves Amgen, Inc. and Sanofi as the two remaining contenders. Both companies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

26 Jun 2025

• By Kevin Grogan

The biotech had been looking at options to survive since May.

Kymera Inks CDK2 Deal With Gilead

25 Jun 2025

• By Alaric DeArment

Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

24 Jun 2025

• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

Stock Watch: When The Biotech Bandwagon Music Stops

24 Jun 2025

• By Andy Smith

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.